Corrigendum to “Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States”

Corrigendum to “Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States”

Bibliographic Details
Main Authors:	Catherine W. Saltus, Zdravko P. Vassilev, Jihong Zong, Brian Calingaert, Elizabeth B. Andrews, Montse Soriano-Gabarró, James A. Kaye
Format:	Article
Language:	English
Published:	Hindawi Limited 2019-01-01
Series:	Prostate Cancer
Online Access:	http://dx.doi.org/10.1155/2019/3425982

Similar Items

Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States
by: Catherine W. Saltus, et al.
Published: (2019-01-01)

Incidence of Skeletal-Related Events in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US
by: Alison Tse Kawai, et al.
Published: (2019-01-01)

Overall survival and second primary malignancies in men with metastatic prostate cancer.
by: Juha Mehtälä, et al.
Published: (2020-01-01)

Incidence of second malignancies for prostate cancer.
by: Mieke Van Hemelrijck, et al.
Published: (2014-01-01)

Early effects of castration therapy in non-malignant and malignant prostate tissue
by: Ohlson, Nina
Published: (2005)

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]
by: Bretoni A, et al.
Published: (2019-08-01)

Second-line hormonal therapy with the enzalutamid in patients with castrate-resistant prostate cancer
by: B. Ya. Alekseev, et al.
Published: (2016-09-01)

Trends in the contemporary incidence of colorectal cancer and patient characteristics in the United Kingdom: a population-based cohort study using The Health Improvement Network
by: Lucía Cea Soriano, et al.
Published: (2018-04-01)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
by: Magdalena Schrank, et al.
Published: (2020-01-01)

Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
by: Meghan A. Rice, et al.
Published: (2019-08-01)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
by: Channing J Paller, et al.
Published: (2011-03-01)

Prostate cancer with bone metastasis in Beijing: an observational study of prevalence, hospital visits and treatment costs using data from an administrative claims database
by: Yi Song, et al.
Published: (2019-06-01)

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study [Corrigendum]
by: Restelli U, et al.
Published: (2018-03-01)

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
by: Seonggyu Byeon, et al.
Published: (2020-11-01)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
by: Vanita Noronha, et al.
Published: (2016-08-01)

Second line chemotherapy in patients with castration-refractory prostate cancer. Ftom clinical studies to practice
by: B. Ya. Alekseev, et al.
Published: (2019-04-01)

Darolutamide For Castration-Resistant Prostate Cancer
by: Bastos DA, et al.
Published: (2019-10-01)

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
by: Keith L. Davis, et al.

Up-regulation of prostatic cannabinoid receptor type 2 following capsaicin-induced prostatitis in castrated and non-castrated rats
by: Alex Tong-Long Lin, et al.
Published: (2016-06-01)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
by: Lixin Mai, et al.
Published: (2020-12-01)

Prognostic significance of time to castration resistance in patients with metastatic castration-sensitive prostate cancer
by: Y. Matsushita, et al.
Published: (2020-07-01)

Real-life data of Cabazitaxel-Prednisone second-line scheme in metastatic castration-resistant prostate cancer
by: L.F. Sánchez-Cousido, et al.
Published: (2020-11-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
by: Oliver Sartor, et al.
Published: (2014-10-01)

Prostate progenitor cells proliferate in response to castration
by: Xudong Shi, et al.
Published: (2014-07-01)

Chemotherapy options in castration-resistant prostate cancer
by: Benjamin A Teply, et al.
Published: (2016-01-01)

Optimal treatment for castration-resistant prostate cancer
by: Kouji Izumi, et al.
Published: (2014-06-01)

Response and Resistance in Castration-Resistant Prostate Cancer
Published: (2020)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
by: Masayoshi Zaitsu, et al.
Published: (2012-01-01)

A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
by: Sang Eun Yoon, et al.
Published: (2019-05-01)

Comparison of efficacy between second line anti-androgen drugs for metastatic castration-resistent prostate cancer patients
by: Po-Jung Su, et al.
Published: (2018)

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
by: Yuki Kita, et al.
Published: (2018-09-01)

Long Noncoding RNA from PVT1 Exon 9 Is Overexpressed in Prostate Cancer and Induces Malignant Transformation and Castration Resistance in Prostate Epithelial Cells
by: Gargi Pal, et al.
Published: (2019-11-01)

Increased Incidence of Second Malignancies Associated with Small Bowel Adenocarcinoma
by: Dianne Ripley, et al.
Published: (1997-01-01)

Study the role of REST in castration resistant prostate cancer
by: Yi-Ting Chang, et al.
Published: (2018)

EXPERIENCE WITH OCTREOTIDE IN PATIENTS WITH CASTRATION REFRACTORY PROSTATE CANCER
by: D. I. Ganov, et al.
Published: (2014-07-01)

Development and prevalence of castration-resistant prostate cancer subtypes
by: Jordan E. Vellky, et al.
Published: (2020-11-01)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
by: Renée de Leeuw, et al.
Published: (2020-10-01)

Radium-223 in metastatic castration resistant prostate cancer
by: Winston Vuong, et al.
Published: (2014-06-01)

Radium-223 for the treatment of castration-resistant prostate cancer
by: El-Amm J, et al.
Published: (2015-05-01)